Share this article
Share this article
NEW YORK, Jan. 26, 2021 /PRNewswire/ Soterix Medical Inc. (SMI), the global leader in non-invasive stimulation and synergistic brain imaging technologies, announces a new clinical trial of home-based auricular Vagus Nerve Stimulation (taVNS) for individuals who experience post-COVID neuropsychiatric symptoms, like fatigue, headache, or anxiety. The trial involves an innovative, first-of-its kind home-based neuromodulation solution that combines Soterix Medical s unique wearable taVNS platform, with ElectraRx™ portal for remote stimulation control, and home-based vital sign monitoring.
Emerging studies show COVID can affect patients during two distinct phases of the disease process: the acute stage, characterized by fever, heart or lung problems, and the post-COVID phase, in which neuropsychiatric symptoms, like fatigue, anxiety and depression, can occur.
Press release content from PR Newswire. The AP news staff was not involved in its creation.
Soterix Medical Announces Expanded Clinical Trials for Alzheimer’s disease and Mild Cognitive Impairment
December 24, 2020 GMT
(PRNewsfoto/Soterix Medical)
NEW YORK, Dec. 24, 2020 /PRNewswire/ Soterix Medical Inc. , the global leader in non-invasive stimulation and synergistic brain imaging technologies, is pleased to report expanded clinical trials of its proprietary neuromodulation technologies for Alzheimer’s disease and Mild Cognitive Impairment. Adults over age 65 represent the fastest growing population in the US. Decline in cognitive abilities is a hallmark of advanced age and is associated with loss of independence and dementia risk. Over 50 million adults worldwide are diagnosed with Alzheimer’s disease or other dementia, which puts an enormous burden on individuals, their families and caretakers, and the healthcare system. Soterix Medical technologies are at the forefront